| Name | Title | Contact Details |
|---|
Rowan Regional Medical Center is a Salisbury, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Arc of Anchorage is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hooper Holmes is a data-driven leader in collecting personal health data and transforming it into useful information, which in turn, enables our customers to take actions that manage or reduce their risks and expenses. As the foremost provider of risk assessment services for the insurance industry, we are the only company that can provide insurers with ALL the services they need to reach their ultimate goal: complete policy medical exam, data collection, laboratory testing, inspection reports and underwriting services in the industry. Each year we arrange more medical exams than any other company and process millions of specimens in our laboratory. And we provide a complete service for wellness, disease management, and managed care companies including scheduling support, fulfillment of supplies, blood collection kits, medical screenings, lab testing and data transmission.
Osmotics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Osmotics is based in Denver, CO. You can find more information on Osmotics at www.osmotics.com
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.